IMS Health (NYSE: RX), the world’s leading provider of market
intelligence to the pharmaceutical and healthcare industries, today
announced the wide-scale availability of its advanced analytical
offering, IMS Specialty Market Dynamics™, which
delivers the most complete view of treatment patterns and product
performance in the rapidly growing specialty pharmaceutical market. The
offering supports clients’ critical commercial applications through
comprehensive coverage of the specialty pharmacy provider channel,
coupled with IMS’s extensive anonymized patient-centered insights.
“This marks a significant advance for our clients that offer specialty
medications, all of whom share a vital interest in a market segment
that’s growing at twice the pace of traditional pharmaceutical
products,” said Pam Sauerwald, general manager, Specialty Offerings
Development, IMS. “As demand for evidence-based information in the
specialty sector grows, we’re uniquely positioned to provide a deeper
understanding into how these products are used – helping clients to
adjust portfolio strategies and improve their commercial effectiveness.”
The IMS offering provides unprecedented insights into channel
dynamics, with longitudinal information from the specialty pharmacy
provider channel that can be applied in combination with retail and
standard mail service channel assessments. This enables clients to
identify trends and growth opportunities relating to utilization,
product switching, compliance and persistence by channel, product usage
by indication, common treatment regimens, and channel-to-channel
dynamics.